AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.

Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...

In a separate development, AbbVie has completed the acquisition of Nimble Therapeutics, which is now integrated into AbbVie's operations. The oral peptide interleukin 23 receptor (IL23R ...

AbbVie ABBV announced that it has entered ... Earlier this week, ABBV completed the acquisition of immunology drugmaker Nimble Therapeutics. With this acquisition, it added Nimble’s innovative ...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...